Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 9, 2022
- Annualized Bleeding Rate (ABR) Reduced by 85% from Baseline, Demonstrating Superiority to Factor VIII ProphylaxisBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the...
-
Jan 4, 2022- Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 6 at 11:00am ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January. To access the...
Dec 16, 2021BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today...
-
Dec 15, 2021
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to...
-
Nov 30, 2021- Multiple Innovative Programs in a Variety of Indications to be Discussed by BioMarin Management and External Speakers
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021. BioMarin management and external experts will provide...
-
Nov 29, 2021- Evercore ISI 4th Annual HealthCONx Conference on December 1 at 1:25pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual investor conferences. An audio webcast of the presentations will be available...
-
Nov 19, 20211st Therapeutic Treatment for Achondroplasia, Most Common Form of Disproportionate Short Stature
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to...
-
Oct 27, 2021- Strong Commercial Launch of VOXZOGO™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding, Target Action Date Tracking to November 20, 2021
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 % Change 2021 2020 % Change Total...
-
Oct 25, 2021- Jefferies Gene Therapy/Editing Summit on October 28 at 2:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual investor conferences. An audio webcast of the presentations will be available...
-
Oct 12, 2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...